Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 25,732 shares, a drop of 58.6% from the August 31st total of 62,228 shares. Based on an average trading volume of 500 shares, the short-interest ratio is currently 51.5 days.

Hansa Biopharma AB (publ) Stock Performance

Hansa Biopharma AB (publ) stock remained flat at $3.70 during midday trading on Monday. Hansa Biopharma AB has a 12 month low of $2.90 and a 12 month high of $3.70. The firm has a 50 day moving average of $3.57 and a 200-day moving average of $3.14.

Analyst Ratings Changes

Separately, Danske began coverage on Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.